MT3 and cancer: Unlike MT1 and MT2, the status of MT3 expression has been found rather inconsistent among different cancer types, upregulated in some cancers (i.e. breast, prostate, urinary bladder, and lung cancers)8–12, while downregulated in others (i.e. gastric and esophageal cancers and leukemia)13–15.